The minimal residual disease (MRD) testing market reached a turning point in 2025 as pivotal trial readouts, commercial alliances and consolidation advanced clinical validation. The Phase III IMvigor011 trial used Natera’s tumor‑informed Signatera ctDNA test to select muscle‑invasive bladder cancer patients for adjuvant Tecentriq and reported a significant survival benefit in Signatera‑positive patients presented at ESMO. The IMvigor011 results, coupled with other trial data and commercial activity, accelerated payer and regulatory conversations; Natera is finalizing a premarket application to the FDA for Signatera as a companion diagnostic for Tecentriq selection. The MRD field also saw acquisitions and reimbursement wins in 2025, signaling increased commercialization and clinical adoption. For oncology stakeholders, MRD’s randomized trial evidence represents a milestone toward integrating liquid‑biopsy biomarkers into adjuvant treatment decisions and guidelines.